-+ 0.00%
-+ 0.00%
-+ 0.00%
iBio Presents New Preclinical Data Across Obesity and Cardiometabolic Portfolio At PEGS Europe 2026 And Amylin-Based Therapeutics Summit
Share
Listen to the news

ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.

Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit

Together, the findings highlight the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending